The contrast observation of the vitreous cavity injection of Combercept or Ranibizumab to treat wet age-related macular degeneration

Objective To explore the clinical efficacy and safety, and to make the contrast obser-vation by using vitreous cavity injection of Combercept and Ranibizumab to treat wet age-related macular degeneration. Methods Clinical case control study. From June 2014 to June 2016, 103 patients (103 eyes) with wet AMD were enrolled in the second people's Hospital of Zhengzhou. ETDRS visual acuity chart, color fundus, fundus fluorescein angiography (FFA) and optical coherence tomography (OCT) were used to confirm the diagnosis. The patients were randomly divided into two groups according to random number table method, one group for Combercept treatment group (52 cases, 52 eyes) given the vitreous body cavity injection of 10 g/L Combercept of 0.05 ml (0.5 mg containing Combercept); one group for Ranibizumab treatment group (51 cases, 51 eyes) given vitreous body cavity injection of 0.05 ml (0.5 mg containing Ranibizumab). ETDRS visual acuity, macular center concave retinal thickness and choroid neovascularization (CNV) leakage of the two groups before and after treatment were follow-up for 10.65±2.27 months compared. Results Vitre-ous body injection therapy was 3 to 5 times for either Combercept or Ranibizumab, the average number of treatment was 3.65 times. ETDRS visual acuity compared with before treatment, the two groups were statistically significant (P <0.01) in 103 eyes after treatment at the end of the follow-up examination; The macular center concave retinal thickness was statistical significance between the two groups (P <0.01) compared with before treatment; Combercept treatment group: the macular area fluorescence leakage stopped in 28 eyes, reduce leakage 20 eyes, no obvious change in four eyes, Ranibizumab treatment group: the macular area fluorescence leakage stopped in 26 eyes, reduce leakage in 22 eyes, 3 eye had no obvious change. The two groups had no obvious statistics significant difference. Follow-up period had no injection and drug related ocular and systemic adverse reactions occur. Conclusions Vitreous cavity injection of Combercept or Ranibizumab for treatment of wet AMD has good curative effect. It can obviously increase the visual acuity, reduce the macular edema, and inhibit leakage of angiogenesis. There is no statistical difference between the two groups. Key words: Wet AMD; Combercept; Ranibizumab; Intravitreal injection; OCT; FFA